ODINK DEBRA 4
4 · Anthera Pharmaceuticals Inc · Filed Feb 3, 2012
Insider Transaction Report
Form 4
ODINK DEBRA
VP, Pharmaceutical R&D
Transactions
- Sale
Common Stock
2012-02-01$7.67/sh−2,000$15,340→ 21,241 total
Holdings
- 95,928(indirect: By Trust)
Common Stock
Footnotes (2)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2011.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.55 to $7.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares sold at each separate price within the range set forth in this footnote.